Search Results - "LEISSINGER, C."

Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders by Leissinger, C., Carcao, M., Gill, J. C., Journeycake, J., Singleton, T., Valentino, L.

“…Summary Bleeding disorders, including haemophilia, von Willebrand disease, and platelet function abnormalities pose a substantial, ongoing management…”
Get full text

Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program by Christopherson, Pamela A., Haberichter, Sandra L., Flood, Veronica H., Perry, Crystal L., Sadler, Brooke E., Bellissimo, Daniel B., Di Paola, Jorge, Montgomery, Robert R., Abshire, T, Weiler, H, Lillicrap, D, James, P, O’Donnell, J, Ng, C, Bennett, C, Sidonio, R, Manco‐Johnson, M, Journeycake, J, Zia, A, Lusher, J, Rajpurkar, M, Shapiro, A, Lentz, S, Gill, J, Leissinger, C, Ragni, M, Tarantino, M, Roberts, J, Hord, J, Strouse, J, Ma, A, Valentino, L, Boggio, L, Sharathkumar, A, Gruppo, R, Kerlin, B, Kulkarni, R, Green, D, Hoots, K, Brown, D, Mahoney, D, Mathias, L, Bedros, A, Diamond, C, Neff, A, DiMichele, D, Giardina, P, Cohen, A, Paidas, M, Werner, E, Matsunaga, A, Shafer, F, Konkle, B, Cuker, A, Kouides, P, Stein, D

“…Background Type 3 von Willebrand Disease (VWD) is a rare and severe form of VWD characterized by the absence of von Willebrand factor (VWF). Objectives As part…”
Get full text

Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A by Klamroth, R., Simpson, M., von Depka-Prondzinski, M., Gill, J. C., Morfini, M., Powell, J. S., Santagostino, E., Davis, J., Huth-Kühne, A., Leissinger, C., Neumeister, P., Bensen-Kennedy, D., Feussner, A., Limsakun, T., Zhou, M., Veldman, A., St. Ledger, K., Blackman, N., Pabinger, I.

“…Background rVIII‐SingleChain, a novel recombinant factor VIII (rFVIII), has been designed as a B‐domain truncated construct with covalently bonded heavy and…”
Get full text

Laboratory variability in the diagnosis of type 2 VWD variants by DiGiandomenico, Stefanie, Christopherson, Pamela A., Haberichter, Sandra L., Abshire, Thomas C., Montgomery, Robert R., Flood, Veronica H., Valentino, L., Abshire, T., Dunn, A., Bennett, C., Lusher, J., Rajpurkar, M., Hoots, W. K., Brown, D., Shapiro, A., Paola, J. Di, Lentz, S., Gill, J., Leissinger, C., Ragni, M., Hord, J., Manco‐Johnson, M., Ma, A., Boggio, L., Sharathkumar, A., Gruppo, R., Kerlin, B., Journeycake, J., Kulkarni, R., Mahoney, D, Mathias, L., Bedros, A., Diamond, C., Neff, A., Paroskie, A., DiMichele, D., Giardina, P., Cohen, A., Paidas, M., Werner, E., Matsunaga, A., Singer, T., Tarantino, M., Roberts, J., Shafer, F., Konkle, B., Cuker, A., Kouides, P., Stein, D., Manco‐Johnson, M., Dunn, A., Bennett, C., Journeycake, J., Lusher, J., Rajpurkar, M., Shapiro, A., Lentz, S., Lillicrap, D., James, P., Leissinger, C., Roberts, J., Ragni, M.

“…Essentials Patients with von Willebrand disease were enrolled in our study. Type 2 VWD diagnoses were based on original test results. Repeat evaluation…”
Get full text

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia by Carcao, M. D., Avila, L., Leissinger, C., Blanchette, V. S., Aledort, L.

Get full text

Prophylaxis re‐visited: The potential impact of novel factor and non‐factor therapies on prophylaxis by Carcao, M., Lambert, T., Leissinger, C., Escuriola‐Ettingshausen, C., Santagostino, E., Aledort, L.

Get full text

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia by Carcao, M. D., Avila, L., Leissinger, C., Blanchette, V. S., Aledort, L.

Get full text

Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study by Gringeri, A., Leissinger, C., Cortesi, P. A., Jo, H., Fusco, F., Riva, S., Antmen, B., Berntorp, E., Biasoli, C., Carpenter, S., Kavakli, K., Morfini, M., Négrier, C., Rocino, A., Schramm, W., Windyga, J., Zülfikar, B., Mantovani, L. G.

“…Summary Patients with haemophilia A and inhibitors are at high risk for severe bleeding, progression of joint disease and deterioration of health‐related…”
Get full text

Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A by LEISSINGER, C., COOPER, D. L., SOLEM, C. T.

“…Few data exist on the impact of age and inhibitor status on activity levels among patients with severe and moderately severe haemophilia A. The aim of this…”
Get full text

Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population by DU TREIL, S., RICE, J., LEISSINGER, C. A.

“…It is known that chronically ill patients adhere to medical treatment plans only 50% of the time [1]. Adherence to treatment with factor infusion therapy in…”
Get full text

Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States by THORNBURG, C. D., CARPENTER, S., ZAPPA, S., MUNN, J., LEISSINGER, C.

“…The primary goal of prophylaxis in patients with severe haemophilia is to convert the phenotype from severe to moderate and to prevent the development of…”
Get full text

Opinions on radiosynovectomy for chronic haemophilic synovitis: point/counterpoint by Silva, M., Luck, J. V., Leissinger, C.

“…Summary Joint bleeding is the hallmark of severe haemophilia and the major cause of disability in patients with this coagulopathy. Repeated bleeding into the…”
Get full text

Prophylactic treatment with activated prothrombin complex concentrate (FEIBA®) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors by LEISSINGER, C. A., BECTON, D. L., EWING, N. P., VALENTINO, L. A.

“…Orthopaedic complications are among the most disabling sequelae occurring in patients with haemophilia and inhibitors. Recurrent or refractory joint bleeds can…”
Get full text

Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII by Gelhorn, H., Merikle, E., Krishnan, S., Nemes, L., Leissinger, C., Valentino, L.

“…Summary Prophylaxis may be beneficial for patients with severe haemophilia A who have developed inhibitors to factor VIII. The aim of this study was to…”
Get full text

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference by BERNTORP, E., SHAPIRO, A., ASTERMARK, J., BLANCHETTE, V. S., COLLINS, P. W., DIMICHELE, D., ESCURIOLA, C., HAY, C. R. M., HOOTS, W. K., LEISSINGER, C. A., NEGRIER, C., OLDENBURG, J., PEERLINCK, K., REDING, M. T., HART, C.

“…Participants in an international conference on the management of haemophilia patients with inhibitors developed a jointly authored summary of the findings and…”
Get full text

Prophylaxis in haemophilia patients with inhibitors by LEISSINGER, C. A.

“…The presence of high titre inhibitors makes the treatment of bleeding episodes in haemophilia patients difficult and increases the risk of uncontrollable…”
Get full text

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors by TEITEL, J., BERNTORP, E., COLLINS, P., D'OIRON, R., EWENSTEIN, B., GOMPERTS, E., GOUDEMAND, J., GRINGERI, A., KEY, N., LEISSINGER, C., MONAHAN, P., YOUNG, G.

“…The presence of inhibitory antibodies to clotting factors complicates the treatment of bleeding in haemophilia patients. For patients with high‐titre…”
Get full text

PGI35 Health-Related Quality of Life in Patients With Haemophilia and Inhibitors on Prophylaxis With Anti-Inhibitor Complex Concentrate: Results From the Pro-Feiba Study by Gringeri, A, Leissinger, C, Cortesi, P.A, Fusco, F, Riva, S, Mantovani, L.G

Get full text

PSY20 Cost-Effectiveness of Prophylaxis With an Anti-Inhibitor Complex Concentrate in Patients With Haemophilia and Inhibitors: Results From Pro-Feiba Study by Gringeri, A, Leissinger, C, Cortesi, P.A, Cristiani, M, Fusco, F, Mantovani, L.G

Get full text

Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors by Valentino, L. A., Allen, G., Gill, J. C., Hurlet, A., Konkle, B. A., Leissinger, C. A., Luchtman-Jones, L., Powell, J., Reding, M., Stine, K.

“…Summary In haemophilia patients with well‐established high‐titer inhibitors, even seemingly minor acute bleeding episodes or surgical procedures may become…”
Get full text